NZ330451A - - Google Patents

Info

Publication number
NZ330451A
NZ330451A NZ330451A NZ33045197A NZ330451A NZ 330451 A NZ330451 A NZ 330451A NZ 330451 A NZ330451 A NZ 330451A NZ 33045197 A NZ33045197 A NZ 33045197A NZ 330451 A NZ330451 A NZ 330451A
Authority
NZ
New Zealand
Prior art keywords
formula
r4so2
r2co
interleukin
substituents
Prior art date
Application number
NZ330451A
Other languages
English (en)
Inventor
Donald S Karanewsky
Steven D Linton
Original Assignee
Idun Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idun Pharmaceuticals Inc filed Critical Idun Pharmaceuticals Inc
Publication of NZ330451A publication Critical patent/NZ330451A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dentistry (AREA)
NZ330451A 1996-09-12 1997-09-12 NZ330451A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2601196P 1996-09-12 1996-09-12
US71062196A 1996-09-20 1996-09-20

Publications (1)

Publication Number Publication Date
NZ330451A true NZ330451A (enExample) 2000-01-28

Family

ID=26700599

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ330451A NZ330451A (enExample) 1996-09-12 1997-09-12

Country Status (8)

Country Link
EP (1) EP0874850B1 (enExample)
JP (1) JP2000501428A (enExample)
AT (1) ATE215953T1 (enExample)
AU (1) AU739496B2 (enExample)
CA (1) CA2237314A1 (enExample)
DE (1) DE69711845T2 (enExample)
NZ (1) NZ330451A (enExample)
WO (1) WO1998011109A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
JP4499917B2 (ja) 1998-03-09 2010-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビターとしての１，２−ジアゼパン誘導体
EP1076563B1 (en) * 1998-03-16 2005-05-11 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
KR100898094B1 (ko) 1998-03-19 2009-05-18 버텍스 파마슈티칼스 인코포레이티드 카스파제의 억제제
DE60030097T2 (de) 1999-03-16 2007-03-08 Cytovia, Inc., San Diego Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
JP2002541237A (ja) 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
PT1163208E (pt) 1999-08-06 2004-08-31 Vertex Pharma Inibidores de caspase e as suas utilizacoes
CN1235875C (zh) 1999-08-27 2006-01-11 西托维亚公司 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
CA2386411A1 (en) * 1999-10-13 2001-04-19 Merck Frosst Canada & Co. Nicotinyl aspartyl ketones as inhibitors of caspase-3
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
JP2003535865A (ja) 2000-06-07 2003-12-02 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびその使用
CN102225936B (zh) 2004-03-12 2013-09-11 弗特克斯药品有限公司 制备化合物的方法
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
JP2009502922A (ja) 2005-07-28 2009-01-29 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ阻害剤プロドラッグ
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
JPH09500113A (ja) * 1993-06-30 1997-01-07 チバ−ガイギー アクチェンゲゼルシャフト エンケファリナーゼ及びａｃｅのインヒビターとして有用な抗高血圧性三環式アゼピン誘導体

Also Published As

Publication number Publication date
AU4583597A (en) 1998-04-02
WO1998011109A1 (en) 1998-03-19
EP0874850A1 (en) 1998-11-04
DE69711845D1 (de) 2002-05-16
ATE215953T1 (de) 2002-04-15
EP0874850B1 (en) 2002-04-10
AU739496B2 (en) 2001-10-11
DE69711845T2 (de) 2002-10-31
JP2000501428A (ja) 2000-02-08
CA2237314A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
NZ330451A (enExample)
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
AU688952B2 (en) Thrombin inhibitors
MX9703564A (es) Inhibidores de proteasa multicatalitica.
IL138402A0 (en) Heterocyclically substituted amides used as calpain inhibitors
AU3115395A (en) Dihydrobenzofuranes
BG103485A (en) Ketobanzamides as calpain inhibitors
SI0797439T1 (en) Use of pramipexole as a neuroprotective agent
MY121222A (en) Prodrugs of thrombin inhibitors
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
DE69728594T2 (de) Chromfreie Zusammensetzung für die Behandlung von metallischen Oberflächen
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
TR199800773T2 (xx) Trombin inhibit�rleri.
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
ZA986673B (en) Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders
MXPA01010403A (es) Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
ZA961364B (en) 1-Aryl-2-acylamino-ethane compounds
AU8320691A (en) Inhibitors of retroviral proteases
MX9801190A (es) Inhibidores de prolil endopeptidasa.
BG105539A (bg) Елетриптан хидробромид монохидрат
GB2324091A (en) Metalloproteinase inhibitors
AP9400632A0 (en) Ether derivatives.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)